

MNKD Products & Pipeline

	Product (Collaboration and/or details)	Targeted Indication(s)	Pre-IND / Formulation	Phase 1	Phase 2	Phase3 / Pivotal	Marketed
Endocrine	Afrezza® (insulin human) Inhalation Powder – <u>USA</u>	T1 and T2 diabetes mellitus (adults)	→				→
	Afrezza® (insulin human) Inhalation Powder – <u>INT'L</u> Brazil (Biommm); India (Cipla)	T1 and T2 diabetes mellitus (adults)	→ India				→ Brazil
	Pediatric Afrezza® (insulin human) Inhalation Powder Indication Expansion	T1 and T2 diabetes mellitus (pediatrics)	→				
	V-Go® (once-daily wearable insulin delivery device)	management of diabetes mellitus in persons requiring insulin (adults)					→
Orphan Lung	Tyvaso DPI® (Collaboration with United Therapeutics)	pulmonary arterial hypertension / pulmonary hypertension associated with interstitial lung disease	→				→
	MNKD-101 (clofazimine)	nontuberculous mycobacterial lung disease	→				
	MNKD-201 (nintedanib)	idiopathic pulmonary fibrosis	→				
	MNKD-301 (dornase alfa)	cystic fibrosis	→				
	MNKD-501 (TGF-β) (Collaboration with Thirona Bio)	idiopathic pulmonary fibrosis	→				